{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:30:21Z","timestamp":1777624221718,"version":"3.51.4"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,26]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n \n The glycated haemoglobin fraction A\n 1c<\/jats:sub>\n (HbA\n 1c<\/jats:sub>\n ) is widely used in the management of diabetes mellitus, and the Siemens DCA Vantage\u2122 point-of-care testing (POCT) instrument offers rapid HbA\n 1c<\/jats:sub>\n results even far from a clinical laboratory. However, the analytical performance has been questioned, and not much is known about effects of changing reagent lot, instrument and operator. We therefore compared the analytical performance of the DCA Vantage\u2122 with established routine methods (Tosoh G8\/G11 ion exchange HPLC) in a true clinical setting at two Danish hospitals.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We extracted all routine clinical HbA\n 1c<\/jats:sub>\n results incidentally drawn from the same patient within 48\u00a0h (n=960 pairs) and evaluated the effect of reagent lot, operator and instrument. We also performed a prospective method comparison in our diabetes out-patient clinic (n=97).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The critical difference (CD) between two POCT results varied between 5.14 and 6.61\u00a0mmol\/mol (0.47\u20130.55%), and the analytical imprecision of the DCA Vantage\u2122 (CV\n A<\/jats:sub>\n ) was >3%. Significant effect of reagent lot and inter-instrument differences were found, whereas no effect of operator was seen.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The DCA Vantage\u2122 HbA\n 1c<\/jats:sub>\n analysis does not fulfil the prevailing analytical performance specifications, but rigorous validation of new reagent lots and continuous recalibration of instruments may potentially improve the precision substantially. Our findings, therefore, clearly emphasise the necessity of a close collaboration between clinicians and laboratory professionals in the POCT field. Finally, POCT HbA\n 1c<\/jats:sub>\n results should always be interpreted together with other measures of glycaemic control to avoid inappropriate change of patient treatments due to measurement uncertainty.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/cclm-2021-0720","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T16:20:30Z","timestamp":1630772430000},"page":"127-134","source":"Crossref","is-referenced-by-count":6,"title":["Lot variation and inter-device differences contribute to poor analytical performance of the DCA Vantage\u2122 HbA\n 1c<\/sub>\n POCT instrument in a true clinical setting"],"prefix":"10.1515","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-0953","authenticated-orcid":false,"given":"Anders","family":"Abildgaard","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry , Regional Hospital Horsens , Horsens , Denmark"},{"name":"Steno Diabetes Center Aarhus , Aarhus University Hospital , Aarhus N , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy S\u00f8nders\u00f8","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry , Aarhus University Hospital , Aarhus N , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise N\u00f8rkj\u00e6r","family":"Bjerg","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry , Regional Hospital Central Jutland , Viborg , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sten","family":"Lund","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Aarhus , Aarhus University Hospital , Aarhus N , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"St\u00f8y","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Aarhus , Aarhus University Hospital , Aarhus N , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"2026042823143773317_j_cclm-2021-0720_ref_001","doi-asserted-by":"crossref","unstructured":"International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327\u201334. https:\/\/doi.org\/10.2337\/dc09-9033.","DOI":"10.2337\/dc09-9033"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_002","doi-asserted-by":"crossref","unstructured":"Laiteerapong, N, Ham, SA, Gao, Y, Moffet, HH, Liu, JY, Huang, ES, et al.. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the diabetes & aging study). Diabetes Care 2019;42:416\u201326. https:\/\/doi.org\/10.2337\/dc17-1144.","DOI":"10.2337\/dc17-1144"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_003","doi-asserted-by":"crossref","unstructured":"Jeppsson, JO, Kobold, U, Barr, J, Finke, A, Hoelzel, W, Hoshino, T, et al.. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78\u201389. https:\/\/doi.org\/10.1515\/CCLM.2002.016.","DOI":"10.1515\/CCLM.2002.016"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_004","doi-asserted-by":"crossref","unstructured":"Lenters-Westra, E, English, E. Understanding the use of sigma metrics in hemoglobin A1c analysis. Clin Lab Med 2017;37:57\u201371. https:\/\/doi.org\/10.1016\/j.cll.2016.09.006.","DOI":"10.1016\/j.cll.2016.09.006"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_005","doi-asserted-by":"crossref","unstructured":"Kristensen, T, Waldorff, FB, Nexoe, J, Skovsgaard, CV, Olsen, KR. Variation in point-of-care testing of HbA1c in diabetes care in general practice. Int J Environ Res Publ Health 2017;14:1363. https:\/\/doi.org\/10.3390\/ijerph14111363.","DOI":"10.3390\/ijerph14111363"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_006","doi-asserted-by":"crossref","unstructured":"Shephard, M, O\u2019Brien, C, Burgoyne, A, Croft, J, Garlett, T, Barancek, K, et al.. Review of the cultural safety of a national Indigenous point-of-care testing program for diabetes management. Aust J Prim Health 2016;22:368\u201374. https:\/\/doi.org\/10.1071\/py15050.","DOI":"10.1071\/PY15050"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_007","doi-asserted-by":"crossref","unstructured":"Whitley, HP, Yong, EV, Rasinen, C. Selecting an A1C point-of-care instrument. Diabetes Spectr 2015;28:201\u20138. https:\/\/doi.org\/10.2337\/diaspect.28.3.201.","DOI":"10.2337\/diaspect.28.3.201"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_008","doi-asserted-by":"crossref","unstructured":"Lenters-Westra, E, Slingerland, RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem 2010;56:44\u201352. https:\/\/doi.org\/10.1373\/clinchem.2009.130641.","DOI":"10.1373\/clinchem.2009.130641"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_009","doi-asserted-by":"crossref","unstructured":"Lenters-Westra, E, Slingerland, RJ. Three of 7 hemoglobin A1c point-of-care instruments do not meet generally accepted analytical performance criteria. Clin Chem 2014;60:1062\u201372. https:\/\/doi.org\/10.1373\/clinchem.2014.224311.","DOI":"10.1373\/clinchem.2014.224311"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_010","doi-asserted-by":"crossref","unstructured":"Nielsen, AA, Petersen, PH, Green, A, Christensen, C, Christensen, H, Brandslund, I. Changing from glucose to HbA1c for diabetes diagnosis: predictive values of one test and importance of analytical bias and imprecision. Clin Chem Lab Med 2014;52:1069\u201377. https:\/\/doi.org\/10.1515\/cclm-2013-0337.","DOI":"10.1515\/cclm-2013-0337"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_011","doi-asserted-by":"crossref","unstructured":"Hirst, JA, McLellan, JH, Price, CP, English, E, Feakins, BG, Stevens, RJ, et al.. Performance of point-of-care HbA1c test devices: implications for use in clinical practice - a systematic review and meta-analysis. Clin Chem Lab Med 2017;55:167\u201380. https:\/\/doi.org\/10.1515\/cclm-2016-0303.","DOI":"10.1515\/cclm-2016-0303"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_012","doi-asserted-by":"crossref","unstructured":"Fraser, CG. Reference change values. Clin Chem Lab Med 2012;50:807\u201312. https:\/\/doi.org\/10.1515\/CCLM.2011.733.","DOI":"10.1515\/cclm.2011.733"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_013","doi-asserted-by":"crossref","unstructured":"Kallner, A, Theodorsson, E. Repeatability imprecision from analysis of duplicates of patient samples and control materials. Scand J Clin Lab Invest 2020;80:210\u20134. https:\/\/doi.org\/10.1080\/00365513.2019.1710243.","DOI":"10.1080\/00365513.2019.1710243"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_014","unstructured":"National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Dec 2020 update; 2015."},{"key":"2026042823143773317_j_cclm-2021-0720_ref_015","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (ADA). 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care 2021;44:S15\u201333. https:\/\/doi.org\/10.2337\/dc21-S002.","DOI":"10.2337\/dc21-S002"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_016","unstructured":"Scientific Committee on Quality Assurance (VUK). Analysekvalitetskrav til HbA1c ved brug til diagnostik og monitorering af diabetes. Available from: https:\/\/dskb.dk\/wp-content\/uploads\/2020\/11\/VUK-HbA1c.pdf [Accessed 15 Dec 2020]."},{"key":"2026042823143773317_j_cclm-2021-0720_ref_017","doi-asserted-by":"crossref","unstructured":"Sacks, DB, Arnold, M, Bakris, GL, Bruns, DE, Horvath, AR, Kirkman, MS, et al.. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011;34:e61\u201399. https:\/\/doi.org\/10.2337\/dc11-9998.","DOI":"10.2337\/dc11-9998"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_018","doi-asserted-by":"crossref","unstructured":"Shephard, M, Shephard, A, McAteer, B, Regnier, T, Barancek, K. Results from 15 years of quality surveillance for a National Indigenous Point-of-Care Testing Program for diabetes. Clin Biochem 2017;50:1159\u201363. https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.07.007.","DOI":"10.1016\/j.clinbiochem.2017.07.007"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_019","doi-asserted-by":"crossref","unstructured":"Lenters-Westra, E, Slingerland, RJ. Hemoglobin A1c point-of-care assays; a new world with a lot of consequences!. J Diabetes Sci Technol 2009;3:418\u201323. https:\/\/doi.org\/10.1177\/193229680900300303.","DOI":"10.1177\/193229680900300303"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_020","doi-asserted-by":"crossref","unstructured":"Trautsch, M, Nickerson-Troy, J, Moore, R, Ingari, E, Meretsky, N, Lewis, L, et al.. Clinical effects of calibration of CoaguChek XS PT Test Strips on Anticoagulation Management Services. J Am Pharm Assoc 2020;60:72\u20135. https:\/\/doi.org\/10.1016\/j.japh.2019.09.013.","DOI":"10.1016\/j.japh.2019.09.013"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_021","doi-asserted-by":"crossref","unstructured":"Stavelin, A, Riksheim, BO, Christensen, NG, Sandberg, S. The importance of reagent lot registration in external quality assurance\/proficiency testing schemes. Clin Chem 2016;62:708\u201315. https:\/\/doi.org\/10.1373\/clinchem.2015.247585.","DOI":"10.1373\/clinchem.2015.247585"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_022","doi-asserted-by":"crossref","unstructured":"Kenealy, T, Herd, G, Musaad, S, Wells, S. HbA1c screening in the community: lessons for safety and quality management of a point of care programme. Prim Care Diabetes 2019;13:170\u20135. https:\/\/doi.org\/10.1016\/j.pcd.2018.11.008.","DOI":"10.1016\/j.pcd.2018.11.008"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_023","unstructured":"Clinical and Laboratory Standards Institute (CLSI). EP26-A - user evaluation of between-reagent lot variation; Approved Guideline; Sep 2013."},{"key":"2026042823143773317_j_cclm-2021-0720_ref_024","doi-asserted-by":"crossref","unstructured":"Huang, Y, Campbell, E, Colbourne, B, Power, J, Randell, E. User competency is still a major factor affecting analytical performance of glucose meters in patient service. Clin Biochem 2019;63:66\u201371. https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.11.008.","DOI":"10.1016\/j.clinbiochem.2018.11.008"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_025","doi-asserted-by":"crossref","unstructured":"American Diabetes, A. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S73\u201384. https:\/\/doi.org\/10.2337\/dc21-s006.","DOI":"10.2337\/dc21-S006"},{"key":"2026042823143773317_j_cclm-2021-0720_ref_026","unstructured":"Clinical and Laboratory Standards Institute (CLSI). EP05-A3 - evaluation of precision of quantitative measurement procedures; Oct 2014."},{"key":"2026042823143773317_j_cclm-2021-0720_ref_027","doi-asserted-by":"crossref","unstructured":"Weykamp, C, John, G, Gillery, P, English, E, Ji, L, Lenters-Westra, E, et al.. Investigation of 2 models to set and evaluate quality targets for hb a1c: biological variation and sigma-metrics. Clin Chem 2015;61:752\u20139. https:\/\/doi.org\/10.1373\/clinchem.2014.235333.","DOI":"10.1373\/clinchem.2014.235333"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2021-0720\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2021-0720\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:15:48Z","timestamp":1777418148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2021-0720\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,9,6]]},"published-print":{"date-parts":[[2022,1,26]]}},"alternative-id":["10.1515\/cclm-2021-0720"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2021-0720","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]}}}